Evidence map›Paper›PMID 36232978›Full record

ArticleInternational journal of molecular sciences2022

Intracranial Virotherapy for a Canine Hemangioma.

Pablo Delgado-Bonet, Beatriz Davinia Tomeo-Martín, Blanca Delgado-Bonet, David Sardón-Ruiz, Angel Torrado-Carvajal, Isidro Mateo, Ana Judith Perisé-Barrios

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pablo Delgado-BonetBiomedical Research Unit (UIB-UAX), Universidad Alfonso X el Sabio, 28691 Madrid, Spain.ORCID 0000-0002-6638-3863
Beatriz Davinia Tomeo-MartínBiomedical Research Unit (UIB-UAX), Universidad Alfonso X el Sabio, 28691 Madrid, Spain.ORCID 0000-0002-7720-4162
Blanca Delgado-BonetMedical Image Analysis and Biometry Laboratory, Universidad Rey Juan Carlos, 28933 Madrid, Spain.ORCID 0000-0003-4635-3541
David Sardón-RuizDepartment of Veterinary Pathology, Universidad Alfonso X el Sabio, 28691 Madrid, Spain.
Angel Torrado-CarvajalMedical Image Analysis and Biometry Laboratory, Universidad Rey Juan Carlos, 28933 Madrid, Spain.ORCID 0000-0002-1540-2809
Isidro MateoNeurology Service, Veterinary Hospital VETSIA, 28914 Madrid, Spain.ORCID 0000-0002-2667-9459
Ana Judith Perisé-BarriosBiomedical Research Unit (UIB-UAX), Universidad Alfonso X el Sabio, 28691 Madrid, Spain.ORCID 0000-0002-0136-3968
Universidad Alfonso X el Sabio · ESUniversidad Rey Juan Carlos · ES

Funding

Comunidad de Madrid PEJD-2019 PRE_BMD-16840Santander Universidades-Fundación Universidad Alfonso X el Sabio 1.013.001
6 · The paper itself

Abstract

Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient's prognosis therefore usually worsens due to tumor progression, and adjuvant treatments are required to control the disease. Oncolytic viruses are an innovative approach that lyses the tumor cells and induces immune responses. Here, we report the intratumoral inoculation of ICOCAV15 (an oncolytic adenovirus) in a canine intracranial hemangioma, as adjuvant treatment for incomplete tumor resection. The canine patient showed no side effects, and the tumor volume decreased over the 12 months after the treatment, as measured by magnetic resonance imaging using volumetric criteria. When progressive disease was detected at month 18, a new dose of ICOCAV15 was administered. The patient died 31.9 months after the first inoculation of the oncolytic adenovirus. Furthermore, tumor-infiltrated immune cells increased in number after the viral administrations, suggesting tumor microenvironment activation. The increased number of infiltrated immune cells, the long survival time and the absence of side effects suggest that ICOCAV15 could be a safe and effective treatment and should be further explored as a novel therapy for canine hemangiomas.

Indexed as

HemangiomaNeoplasmsOncolytic VirotherapyOncolytic VirusesAdenoviridaeAnimalsDogsTumor Microenvironmentbrain tumorhemangiomaICOCAV15immunotherapyoncolytic adenovirusvirotherapyvolumetric criteria

Identifiers

PMID36232978
PMCPMC9569716
OpenAlexW4303699291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.